We now demonstrate that the pharmacologic inhibition of cyp27a1 in the setting of hypercholesterolemia is antiatherogenic (Supplementary Fig. 10b), possibly revealing a means to intervene against hypercholesterolemia-related inflammation without disturbing innate or adaptive immune responses. The gene discussed is CYP27A1; the disease is Hypercholesterolemia.